IL6 and breast carcinoma: Elevated pretreatment plasma fibrinogen levels were associated with reduced rates of pathological complete response to neoadjuvant chemotherapy, 3- and 5-year disease-free survival rates, and OS rates in patients with breast cancer [52,53], and high serum levels of IL-6 were associated with tumor metastasis and patient survival [51,54].